Developing a Smoking Cessation Intervention for Methadone Maintained Smokers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01393392|
Recruitment Status : Completed
First Posted : July 13, 2011
Last Update Posted : May 6, 2015
The purpose of this study is to pilot and evaluate, in a randomized controlled trial, the immediate and long-term effects of a newly developed, tailored, intensive smoking cessation intervention among methadone maintained smokers and compared to a control condition (facilitated referral to the NJ Quitline). The newly developed intervention is evidence based, addresses the unique needs of methadone maintained smokers, is intensive, can be tailored to the individual, and builds on the strengths as well as addresses the gaps in previous treatments for methadone maintained smokers.
The investigators hypothesize that: (1) three months and six months after beginning treatment, those in the tailored intervention condition will be more likely to be abstinent from smoking than those in the control intervention condition (primary outcome); (2) there will be a greater relapse rate in the control intervention condition between the three and six month follow-up points than in the tailored intervention condition; (3) three and six months after beginning treatment, those in the tailored intervention condition will have better secondary smoking related outcomes (smoked fewer cigarettes per day in the past week, be more ready to quit, have greater self-efficacy for quitting, experience less nicotine dependence, and be more likely to have made a quit attempt) than those in the control intervention condition; (4) three and six months after beginning treatment, those in the tailored intervention condition will have better utilization of and adherence to smoking cessation pharmacotherapy, better mental and physical health, less perceived stress, greater social support, less drug and alcohol use, and greater involvement in drug and alcohol treatment than those in the control intervention condition; and (5) the newly created tailored intervention will be feasible and acceptable. .
|Condition or disease||Intervention/treatment||Phase|
|Nicotine Dependence Opiate Dependence||Behavioral: Intensive, tailored intervention Behavioral: NJ Quitline Referral||Phase 1|
Most individuals in methadone maintenance treatment are tobacco smokers. Also, people in methadone treatment are more likely to experience the health issues related to smoking than the general population. Yet, research has found that smokers receiving methadone treatment are interested in quitting and receiving tobacco cessation treatment, and people in drug treatment who quit smoking are less likely to use drugs.
To better help methadone maintained smokers quit smoking and prevent them from starting smoking again, we want to evaluate the effects of a new smoking cessation counseling intervention, designed for methadone maintained smokers as compared to a smoking cessation counseling intervention used with the general population.
Eligible participants will:
- Be English speaking (i.e., able to participate in counseling sessions in English and to complete study interviews in English);
- Be enrolled in methadone treatment for at least three months;
- Be able to give informed consent;
- Be willing and able to participate in all study activities;
- Not have taken smoking cessation related medication or participated in smoking cessation counseling in the past six months;
- Have smoked at least 100 cigarettes during their lifetime and currently smoke every day or most days;
- Not currently be pregnant or breastfeeding or plan on getting pregnant or breastfeeding during the next six months;
- Have access to a working telephone; and,
- Be interested in participating in a smoking cessation intervention and quitting smoking within the next six months.
Participants will be randomly assigned to receive either a smoking cessation intervention tailored for methadone maintained smokers or a referral to a smoking cessation program available to the general population (NJ Quitline). Participants assigned to receive the tailored intervention, will participate in approximately eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the participant's methadone clinic. Treatment needs will be assessed during the first session and the intervention will be tailored to participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
Study staff will contact the NJ Quitline for participants assigned to the control condition, and a counselor from the Quitline will call them.
Regardless of treatment assignment, participants will be asked to provide a urine sample for a drug test and pregnancy test (for women) and complete an interview, using a computer or face-to-face, before beginning treatment or receiving the NJ Quitline referral and three months and six months after study enrollment.Each interview will take approximately 45 minutes to one hour to complete.
Participants will receive a $20 gift card for completing each research visit (i.e., computer or face-to-face interview), but will not be reimbursed for counseling visits.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||91 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Developing a Smoking Cessation Intervention for Methadone Maintained Smokers|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
Experimental: Intensive, tailored intervention
Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
Behavioral: Intensive, tailored intervention
Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
Active Comparator: Control Intervention
Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
Behavioral: NJ Quitline Referral
Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
- seven-day point prevalence of smoking abstinence [ Time Frame: three months ]
- mean number of cigarettes smoked per day during the past week [ Time Frame: three months and six months ]
- any quit attempts since enrollment [ Time Frame: three months and six months ]
- readiness for quitting [ Time Frame: three months and six months ]
- self-efficacy for quitting [ Time Frame: three months and six months ]Participant's rating of confidence in ability to quit smoking on a scale from 0 (not at all confident) to 10 (extremely confident).
- nicotine dependence [ Time Frame: three months and six months ]
- three-month prolonged smoking abstinence [ Time Frame: six months ]
- seven-day point prevalence of smoking abstinence [ Time Frame: six months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01393392
|United States, New Jersey|
|Rutgers Robert Wood Johnson Medical School|
|New Brunswick, New Jersey, United States, 08901|
|Principal Investigator:||Nina Cooperman, Psy.D.||Rutgers Robert Wood Johnson Medical School|